Basit öğe kaydını göster

Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs radiotherapy alone in stage IV (>=N2, M0) undifferentiated nasopharyngeal carcinoma: A positive effect on progression-free survival

dc.contributor.authorWİERZBİCKİ, R
dc.contributor.authorMansouri, A
dc.contributor.authorOliveira, J
dc.contributor.authorRaposo, J
dc.contributor.authorKOSMİDİS, PA
dc.contributor.authorPRASAD, U
dc.contributor.authorGANESAN, S
dc.contributor.authorEL GUEDDARİ, B
dc.contributor.authorBACHOUCHİ, M
dc.contributor.authorLİANES, P
dc.contributor.authorPENA, C
dc.contributor.authorESCHWEGE, F
dc.contributor.authorRAHAL, M
dc.contributor.authorDOSEN, .
dc.contributor.authorMERSİC, Z
dc.contributor.authorKRAJİNA, Z
dc.contributor.authorARMAND, JP
dc.contributor.authorBOUHRİS, J
dc.contributor.authorBENHAMOU, E
dc.contributor.authorDUCOURTİEUX, M
dc.contributor.authorAZLI, N
dc.contributor.authorFANDİ, A
dc.contributor.authorTAAMMA, A
dc.contributor.authorBOSQ, J
dc.contributor.authorKLİJANİENKO, J
dc.contributor.authorSİGAL, R
dc.contributor.authorHONG, WK
dc.contributor.authorVOKES, EE
dc.contributor.authorCLARK, JR
dc.contributor.authorLE FLOCH, O
dc.contributor.authorBERNİER, J
dc.contributor.authorALTUN, Musa
dc.contributor.authorONAT, Haluk
dc.contributor.authorCvitkovic, E
dc.contributor.authorTubianaMathieu, M
dc.contributor.authorFountzilas, G
dc.date.accessioned2021-03-04T18:21:04Z
dc.date.available2021-03-04T18:21:04Z
dc.date.issued1996
dc.identifier.citationCvitkovic E., ESCHWEGE F., RAHAL M., DOSEN .., MERSİC Z., KRAJİNA Z., ARMAND J., BOUHRİS J., TubianaMathieu M., Fountzilas G., et al., "Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs radiotherapy alone in stage IV (>=N2, M0) undifferentiated nasopharyngeal carcinoma: A positive effect on progression-free survival", INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, cilt.35, ss.463-469, 1996
dc.identifier.issn0360-3016
dc.identifier.othervv_1032021
dc.identifier.otherav_8a301129-3be2-4e10-afc0-1e16ab31f639
dc.identifier.urihttp://hdl.handle.net/20.500.12627/93685
dc.identifier.urihttps://doi.org/10.1016/s0360-3016(96)80007-1
dc.description.abstractPurpose: Our Phase II trial using bleomycin, epirubicin, and cisplatin (BEG) protocol in the treatment of locoregionally advanced undifferentiated nasopharyngeal carcinoma (UCNT) patients has shown encouraging results with high objective response, disease-free survival, and overall survival rates. To establish the value of this BEC regimen as neoadjuvant chemotherapy, we initiated in 1989 a large international Phase III trial. It compares three cycles of EEC followed by radiotherapy to radiotherapy alone.
dc.language.isoeng
dc.subjectRADYOLOJİ, NÜKLEER TIP ve MEDİKAL GÖRÜNTÜLEME
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectNükleer Tıp
dc.titlePreliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs radiotherapy alone in stage IV (>=N2, M0) undifferentiated nasopharyngeal carcinoma: A positive effect on progression-free survival
dc.typeMakale
dc.relation.journalINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
dc.contributor.department, ,
dc.identifier.volume35
dc.identifier.issue3
dc.identifier.startpage463
dc.identifier.endpage469
dc.contributor.firstauthorID727687


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster